RECRUITINGPhase 2INTERVENTIONAL
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
About This Trial
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Who May Be Eligible (Plain English)
Who May Qualify:
- Be ≥ 18 and ≤ 55 years of age
- Diagnosis of keratoconus in the study eye
Who Should NOT Join This Trial:
- Pregnant, lactating or planning a pregnancy
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Be ≥ 18 and ≤ 55 years of age
* Diagnosis of keratoconus in the study eye
Exclusion Criteria:
* Pregnant, lactating or planning a pregnancy
* Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
Treatments Being Tested
DRUG
GLK-221 Ophthalmic Solution
GLK-221 Ophthalmic Solution administered twice daily to both eyes
DRUG
Placebo Ophthalmic Solution
Placebo Ophthalmic Solution administered twice daily to both eyes
Locations (1)
Glaukos Clinical Study Site
Westerville, Ohio, United States